 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA a leader in full-service, therapeutic antibody discovery and development, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,616,293 common shares of the Company the Common Shares, at a price to the public of 13.45 per Common Share, less und 